학술논문
74P - Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world
Document Type
Abstract
Source
In Annals of Oncology December 2019 30 Supplement 11:xi26-xi26
Subject
Language
ISSN
0923-7534